Premium
The Pharmacology and Toxicology of the ‘Holy Trinity’
Author(s) -
Horsfall Joseph T.,
Sprague Jon E.
Publication year - 2017
Publication title -
basic and clinical pharmacology and toxicology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.805
H-Index - 90
eISSN - 1742-7843
pISSN - 1742-7835
DOI - 10.1111/bcpt.12655
Subject(s) - pharmacology , gabaa receptor , opioid , muscle relaxant , nucleus accumbens , benzodiazepine , chemistry , medicine , dopamine , receptor
Combining opioids with benzodiazepines and skeletal muscle relaxants (‘The Holy Trinity’) has been reported to potentiate the ‘high’. Through unique interactions with colocalized μ‐opioid and GABA A receptors, the combined use of these agents induces a synergistic increase in dopamine in the nucleus accumbens ( NA c) and depression of respiration. The inhibition of GABA release mediated by μ 1 ‐opioid receptor activation results in a subsequent increase in dopamine in the NA c. Benzodiazepines activate the GABA A R to suppress respiration in the medullary respiratory centres. The skeletal muscle relaxant, carisoprodol, appears to bind to a unique binding domain within the GABA A R to further enhance the respiratory depressant effects of the benzodiazepines. Therefore, the opioids, the benzodiazepines and carisoprodol alone or in combination are capable of inducing respiratory depression. Current guidelines for opioid prescribing recommend against the concomitant use of benzodiazepines but do not recognize the potential risk associated with the addition of skeletal muscle relaxants.